Literature DB >> 16144810

Plasminogen activator inhibitor-1 modulates adipocyte differentiation.

Xiubin Liang1, Talerngsak Kanjanabuch, Su-Li Mao, Chuan-Ming Hao, Yi-Wei Tang, Paul J Declerck, Alyssa H Hasty, David H Wasserman, Agnes B Fogo, Li-Jun Ma.   

Abstract

Increased plasminogen activator inhibitor-1 (PAI-1) is linked to obesity and insulin resistance. However, the functional role of PAI-1 in adipocytes is unknown. This study was designed to investigate effects and underlying mechanisms of PAI-1 on glucose uptake in adipocytes and on adipocyte differentiation. Using primary cultured adipocytes from PAI-1(+/+) and PAI-1(-/-) mice, we found that PAI-1 deficiency promoted adipocyte differentiation, enhanced basal and insulin-stimulated glucose uptake, and protected against tumor necrosis factor-alpha-induced adipocyte dedifferentiation and insulin resistance. These beneficial effects were associated with upregulated glucose transporter 4 at basal and insulin-stimulated states and upregulated peroxisome proliferator-activated receptor-gamma (PPARgamma) and adiponectin along with downregulated resistin mRNA in differentiated PAI-1(-/-) vs. PAI-1(+/+) adipocytes. Similarly, inhibition of PAI-1 with a neutralizing anti-PAI-1 antibody in differentiated 3T3-L1 adipocytes further promoted adipocyte differentiation and glucose uptake, which was associated with increased expression of transcription factors PPARgamma, CCAAT enhancer-binding protein-alpha (C/EBPalpha), and the adipocyte-selective fatty acid-binding protein aP2, thus mimicking the phenotype in PAI-1(-/-) primary adipocytes. Conversely, overexpression of PAI-1 by adenovirus-mediated gene transfer in 3T3-L1 adipocytes inhibited differentiation and reduced PPARgamma, C/EBPalpha, and aP2 expression. This was also associated with a decrease in urokinase-type plasminogen activator mRNA expression, decreased plasmin activity, and increased collagen I mRNA expression. Collectively, these results indicate that absence or inhibition of PAI-1 in adipocytes protects against insulin resistance by promoting glucose uptake and adipocyte differentiation via increased PPARgamma expression. We postulate that these PAI-1 effects on adipocytes may, at least in part, be mediated via modulation of plasmin activity and extracellular matrix components.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16144810     DOI: 10.1152/ajpendo.00605.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  29 in total

1.  PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells.

Authors:  Caiyan Zhao; Wei Chen; Liu Yang; Lihong Chen; Stephen A Stimpson; Anna Mae Diehl
Journal:  Biochem Biophys Res Commun       Date:  2006-09-22       Impact factor: 3.575

Review 2.  Adipose tissue: the new endocrine organ? A review article.

Authors:  Susan E Wozniak; Laura L Gee; Mitchell S Wachtel; Eldo E Frezza
Journal:  Dig Dis Sci       Date:  2008-12-04       Impact factor: 3.199

3.  Decreased adipose tissue oxygenation associates with insulin resistance in individuals with obesity.

Authors:  Vincenza Cifarelli; Scott C Beeman; Gordon I Smith; Jun Yoshino; Darya Morozov; Joseph W Beals; Brandon D Kayser; Jeramie D Watrous; Mohit Jain; Bruce W Patterson; Samuel Klein
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

4.  Effect of a 12-month exercise intervention on serum biomarkers of angiogenesis in postmenopausal women: a randomized controlled trial.

Authors:  Catherine Duggan; Liren Xiao; Ching-Yun Wang; Anne McTiernan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-05       Impact factor: 4.254

5.  Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity.

Authors:  Li-Jun Ma; Bridgette A Corsa; Jun Zhou; HaiChun Yang; HaiJing Li; Yi-Wei Tang; Vladimir R Babaev; Amy S Major; MacRae F Linton; Sergio Fazio; Tracy E Hunley; Valentina Kon; Agnes B Fogo
Journal:  Am J Physiol Renal Physiol       Date:  2011-03-02

Review 6.  Scope and mechanisms of obesity-related renal disease.

Authors:  Tracy E Hunley; Li-Jun Ma; Valentina Kon
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-05       Impact factor: 2.894

Review 7.  Biomarkers of obesity and subsequent cardiovascular events.

Authors:  Salma Musaad; Erin N Haynes
Journal:  Epidemiol Rev       Date:  2007-05-10       Impact factor: 6.222

Review 8.  The inflammation highway: metabolism accelerates inflammatory traffic in obesity.

Authors:  Amy R Johnson; J Justin Milner; Liza Makowski
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

Review 9.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 10.  PAI-1 and kidney fibrosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.